Update to the Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) protocol: statistical analysis plan for a prospective, multicenter, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial.

Clicks: 406
ID: 71099
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #15 of 436 articles by views in Trials

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 436 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Observational research suggests that combined therapy with Vitamin C, thiamine and hydrocortisone may reduce mortality in patients with septic shock.The Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) trial is a multicenter, double-blind, adaptive sample size, randomized, placebo-controlled trial designed to test the efficacy of combination therapy with vitamin C (1.5 g), thiamine (100 mg), and hydrocortisone (50 mg) given every 6 h for up to 16 doses in patients with respiratory or circulatory dysfunction (or both) resulting from sepsis. The primary outcome is ventilator- and vasopressor-free days with mortality as the key secondary outcome. Recruitment began in August 2018 and is ongoing; 501 participants have been enrolled to date, with a planned maximum sample size of 2000. The Data and Safety Monitoring Board reviewed interim results at N = 200, 300, 400 and 500, and has recommended continuing recruitment. The next interim analysis will occur when N = 1000. This update presents the statistical analysis plan. Specifically, we provide definitions for key treatment and outcome variables, and for intent-to-treat, per-protocol, and safety analysis datasets. We describe the planned descriptive analyses, the main analysis of the primary end point, our approach to secondary and exploratory analyses, and handling of missing data. Our goal is to provide enough detail that our approach could be replicated by an independent study group, thereby enhancing the transparency of the study.ClinicalTrials.gov, NCT03509350. Registered on 26 April 2018.
Reference Key
lindsell2019updatetrials Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lindsell, Christopher J;McGlothlin, Anna;Nwosu, Samuel;Rice, Todd W;Hall, Alex;Bernard, Gordon R;Busse, Laurence W;Ely, E Wesley;Fowler, Alpha A;Gaieski, David F;Hinson, Jeremiah S;Hooper, Michael H;Jackson, James C;Kelen, Gabor D;Levine, Mark;Martin, Greg S;Rothman, Richard E;Sevransky, Jonathan E;Viele, Kert;Wright, David W;Hager, David N;
Journal Trials
Year 2019
DOI
10.1186/s13063-019-3775-8
URL
Keywords
thiamine sepsis statistical analysis plan steroids vitamin c adaptive sample size septic shock

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.